PURE Protection: PURE Bioscience’s Hard Surface Disinfectant Provides Rapid 30-Second Kill Against Influenza

  PURE Protection: PURE Bioscience’s Hard Surface Disinfectant Provides Rapid
  30-Second Kill Against Influenza

  PURE Hard Surface Ideal for Use in Homes, Offices, Schools, Hospitals and

Business Wire

SAN DIEGO -- January 14, 2013

PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver
dihydrogen citrate (SDC) antimicrobial, is advising its institutional and
household customers of the effectiveness of PURE™ Hard Surface disinfectant in
killing various flu viruses, and emphasizing the product’s 24-hour residual
protection capability. The Company recommends using PURE Hard Surface
disinfectant and food contact surface sanitizer on all high-touch surfaces,
including hand rails, banisters, handles, light switches, doorknobs,
telephones, tabletops, chairs, remote controls, and appliances as well as on
office, manufacturing and technical equipment.

Michael L. Krall, President and CEO of PURE Bioscience, stated, “PURE Hard
Surface provides an aggressive 30-second kill time against a wide range of
viruses, including the dangerous influenza virus. The escalating flu epidemic
poses a serious threat to human health, business and education while
overburdening our healthcare system. Frequent use of PURE Hard Surface can be
an effective preventative tool to stem the spread of germs.”

According to the U.S. Centers for Disease Control and Prevention (CDC) and
various state health agencies, the early arriving 2012-2013 flu season is
resulting in increased illnesses, hospitalizations and deaths with an
intensity not seen for a decade, with 44 states experiencing widespread
influenza. Hospitals are overwhelmed and several metropolitan areas have
declared health emergencies.

PURE Hard Surface’s efficacy against viruses exceeds that of even highly toxic
chemicals, yet it is a fume-free EPA Category IV (least-toxic) product ideal
for use near children, individuals with respiratory challenges and in dense
population environments.

About PURE Hard Surface

US EPA registered PURE Hard Surface disinfectant and food contact surface
sanitizer provides an unparalleled combination of high efficacy and low
toxicity with 30-second bacterial and viral kill times and 24-hour residual
protection when used as directed. SDC-based PURE Hard Surface completely kills
resistant pathogens like MRSA and Carbapenem-resistant Enterobacteriaceae
(Klebsiella pneumoniae NDM-1) and also effectively eliminates dangerous fungi
and viruses including HIV, Hepatitis B, Hepatitis C, Norovirus, Influenza A,
Avian Influenza and H1N1 as well as hazardous food pathogens such as E. coli,
Salmonella and Campylobacter. PURE Hard Surface delivers powerful
broad-spectrum efficacy while remaining classified as least-toxic (Category
IV) by the US EPA, and its active ingredient, SDC, has been determined
Generally Recognized as Safe (GRAS) for use as a biocide on food processing
equipment, machinery and utensils. PURE Hard Surface is available to
individual consumers at http://store.purebio.com.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience
products that provide solutions to numerous global health challenges,
including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity
bioscience technologies, including its silver dihydrogen citrate-based
antimicrobials, represent innovative advances in diverse markets and lead
today’s global trend toward industry and consumer use of “green” products
while providing competitive advantages in efficacy and safety. Patented SDC is
an electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a resistance
to it. PURE is headquartered in El Cajon, California (San Diego metropolitan
area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,”
"expect" or similar expressions. These statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and uncertainties
that could cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, the Company’s cash position and liquidity
requirements, the Company’s failure to implement or otherwise achieve the
benefits of its strategic initiatives, acceptance of the Company's current and
future products and services in the marketplace, the ability of the Company to
develop effective new products and receive regulatory approvals of such
products, competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the Securities
and Exchange Commission. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for revisions or
changes after the date of this release.


PURE Bioscience Investor Contact:
Don Markley, Senior Vice President
(310) 691-7100
PURE Business Contact:
James McClenahan, VP Sales
(619) 596-8600, ext. 145
Press spacebar to pause and continue. Press esc to stop.